Liraglutide to Improve corONary Haemodynamics During Exercise streSS

NCT02315001 on ClinicalTrials.gov · last registry update 2015-05-20

A small phase 2 — 26 participants, against a typical 110. The sponsor logged completion for March 2015. Primary outcome, as filed: Change in rate pressure product at 0.1 mV ST-segment depression.

Status: COMPLETED
Phase: P2
Drug: liraglutide
Saxenda, Victoza, Xultophy
Sponsor: King's College London
Sponsor type: Other
Enrollment: 26
Started: 2014-01
Primary completion: 2015-03 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change in rate pressure product at 0.1 mV ST-segment depression

Conditions studied

Ischaemic Heart Disease · Coronary Heart Disease · Chronic Stable Angina

Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.